Noetic Fund

Aditum Bio brings together unmatched scientific and domain expertise with agile operational capabilities. Our unique investment and operating model enables rapid company formation, planning, and execution to advance novel drug candidates into the clinic and speed their delivery to the patients in need. PROVEN INDUSTRY LEADERSHIP AND SCIENTIFIC EXPERTISE Launched by former Novartis CEO, Joe Jimenez, and former President of the Novartis Institutes for BioMedical Research, Dr. Mark Fishman, the experience of our founding executive team provides Aditum Bio with a unique lens for identifying and selecting innovative drug candidates with unrecognized potential. BETTER OUTCOMES FOR PATIENTS. FASTER RETURNS FOR INVESTORS. By singularly focusing on the translation phase of drug development, Aditum Bio efficiently identifies and develops potentially first- and best-in-class therapies for a broad array of diseases – empowering our ability to reach more patients and creating faster return for its capital investments. OUR VALUES: ROOTED IN SCIENCE, INSPIRED BY PATIENTS Aditum Bio is a new breed of biotech investment firm that is driven to translate science into the new medicines that make a meaningful difference in the lives of patients. We are a dedicated and ambitious team that is tightly aligned by a set of core values that underscore the important work we do. WE ARE PATIENT CENTRIC We have a passion to help patients, and this drives our decision making. We believe that our role is to develop therapies for patients with disorders currently neglected but which are scientifically tractable. WE ARE COLLABORATIVE We believe that we can accomplish more as a team than we can as individuals. We are respectful of each other and listen to understand. We enjoy fierce debate among ourselves to get to the right decision, but in a way that is respectful and appreciative. We pick our colleagues up when they are down. WE ARE CURIOUS We are a collection of people with high learning agility, and believe that no matter what age, we all have much to learn. We change our opinion without hesitation or embarrassment when new facts arise. We seek out the best experts in the world as advisors. WE ARE COURAGEOUS We define the single most important question to a new therapy’s success, then have the courage to answer it. We have a high emotional need to take on challenges and deliver results. We believe it is better to act on 80% of an answer than wait for the remaining 20%. We have the courage to stand up for our beliefs, but the humbleness to consider other viewpoints. FULLFILLING THE PROMISE OF SCIENCE Genetic, genomic and artificial intelligence have led to the discovery of new drug targets and therapeutic modalities; however, many drug candidates fail to be developed due to strategic decisions and high clinical trial expense. Aditum Bio stands apart in the biotech venture capital arena through our differentiated approach for identifying promising, clinic-ready therapies that offer value for underserved patient populations, in areas such as obesity, depression, substance abuse, renal disease, and infectious diseases. ACCELERATING BIOTECH COMPANY FORMATION Harnessing our experienced in-house R&D domain experts as the foundation of our agile operating model, Aditum Bio is able to accelerate the formation and ramp-up of its portfolio companies. We augment each company's newly-established, dedicated leadership team with medical and scientific experts. Operating under the Aditum Bio umbrella in a lean and efficient management structure, portfolio companies are empowered to rapidly progress newly-acquired drug candidates into Phase 2 clinical trials. LEVERAGING TECHNOLOGY FOR EFFICIENT TRIAL EXECUTION Aditum Bio’s strategic advantage extends to its proven acumen for using an array of powerful technologies and digital tools throughout its portfolio companies to support clinical trial execution at the highest level of efficiency. Through our in-house technology capabilities and our extensive partnerships with leading solutions providers, we enable therapies to advance more quickly and at lower cost than in traditional R&D models.

Cathay Health is dedicated to investing in companies at the convergence of life sciences, healthcare and technology with positive impact on human health. With a reach spanning key bio and tech hubs around the globe, we help companies scale across borders and access new markets, partners and patients. Our Strategy We back venture- and growth-stage companies with emerging technologies that catalyze groundbreaking advances in healthcare. We fund future leaders in tech-enabled medicine with differentiated approaches and strong intellectual property to personalize care, improve access and lower cost. We invest in Series A to C rounds with the ability to lead or co-invest, and help companies scale across borders. Our Focus AreasLife Science Tools Diagnostics Clinical Trial Innovation New Care Models Novel Devices & Materials Enabling Technologies For Advanced Therapies Why Cathay HealthA global platform catalyzing cross-industry collaboration: Cathay Health is affiliated to Cathay Capital – a global investment platform connecting partners and catalyzing collaborations across Europe, North America and Asia to solve the world’s most pressing challenges. Scaling companies to transform health across borders: Our global network and operating expertise across regions allows us to grow impactful companies that serve patients worldwide. Deep expertise in both healthcare and technology: Our unique expertise allows us to identify investment opportunities with the largest impact on human health and care. Investing & operating at the convergence Our team not only invests – but brings operating experience – at the convergence of life sciences, healthcare and tech. Our expertise uniquely bridges these complementary fields to maximize the potential of our portfolio companies.

We build and invest in companies that positively impact human health with smart solutions, breakthrough science and technology. Our focus is on innovation in digital healthcare, connected medical devices, and life sciences We focus on therapeutic and preventive technology solutions addressing unmet needs in some of the most vulnerable segments of society: women, children and the elderly. Digital transformation will continue to shape our lives and has the potential to transform care. We aim to build and support Digital Health & Life Sciences companies working to make healthcare smarter, using data to improve care and outcomes, and reinventing the patient journey. Our vision for the future of healthcare guides our investment strategy. A data driven digital transformation will shape the future of healthcare. The traditional biopharma model will evolve into an integrated model, where prevention, precision cure, and care management will coexist in a highly personalized patient-centric solution. Our goal is to support the creation of life transforming care products and therapies. We believe the future of healthcare lies in supporting the next-generation of founders and teams who will lead us there. What do we look for?Innovation and groundbreaking opportunities in our sectors of focus: digital health, life sciences, tech-enabled care delivery, and connected devices Innovative treatments for Central Nervous System (CNS) disorders, in particular neurodevelopmental disorders, mental health and epilepsy Founders and teams with domain expertise who seek collaborative investment partners Investments that span development and commercial phases, with a focus on early stage opportunities (Pre-Seed to Series A). Our investment approachOur investment approach combines direct investments in early-stage companies with venture creation from bold ideas in global innovation hubs Our goal is to enable talented entrepreneurs to scale more quickly and effectively through access to our capital, enterprise capabilities and consumer touchpoints, while offering expertise and insights from Angelini’s unique perspective. We invest primarily across Europe, North America and Israel, recognizing that healthcare technology innovation is occurring in many cities around the world. We have committed €300M for investments and company creation in digital health and life sciences. What do we commit to you?Active and involved healthcare investors who operate with integrity, approachability, and transparency A team of passionate healthcare and venture capital experts diverse in demographic and experience A track record of success and experience navigating the ups and downs of early-stage company building Access to a world-class advisory board to leverage C-level experience, expertise, and leadership in healthcare

SCOR Ventures is the venture investment arm of SCOR Reinsurance, responsible for both investing in and creating partnerships with startups across the insurtech landscape. Since 2017 we have built a global portfolio across three theses: (1) investing in tech-driven underwriting companies (MGAs, carriers) and distributors, (2) software solutions that benefit SCOR and/or our clients, and (3) companies that help people live healthier lives. Our investment scope includes both investments and commercial (re)insurance relationships with startups. We predominantly invest at late Seed / Series A and are interested in a broad range of B2B and B2B2C solutions across MedTech, wellness, wearables, data platforms, and software / AI platforms. What we’re looking for We invest across three thesis areas: Thesis 1: we invest and partner in the ‘Insurers of the Future’: tech-driven underwriting companies (MGAs, carriers) that offer multiple points of digital and business model differentiation across P&C and L&H. We provide direct access to SCOR expertise and our global network to help portfolio companies scale and/or access (re)insurance capacity. With a proven track record of supporting innovative underwriting propositions across multiple lines of business, we understand product development, program structuring, underwriting, pricing and distribution and thus have the capabilities to optimise partnerships between insurtechs and business partners. We predominantly invest at late Seed / Series A. We are class of business agnostic and have partnered with companies across a broad variety of personal and specialty lines. Thesis 2: we invest and partner in software solutions that benefit SCOR and/or our clients. We provide a broad understanding of the interests and pain points of insurers across the world, and the potential to connect companies with insurers through SCOR’s client services initiatives. We predominantly invest later stage vs. Thesis 1 (typically Series A-B) but have occasional appetite for Seed. We prioritise companies: developing data, tools, and methods for obtaining, understanding, pricing and transferring large portfolios of pre-aggregated risks, high-value individual risks such as energy facilities and construction mega-projects, and MGA/coverholder business delivering economically valuable additional services offering a visible outcome which can be used to boost client management or reduce risks. Focus areas include front-end (e.g., underwriting & pricing) policy administration, modelling, risk analytics, and claims developing platforms where insurance has not previously been embedded / distributed, but where SCOR Ventures sees substantial opportunities to close the global protection gap – e.g., marketplaces, “super apps”, b2b fintech, employee benefits working to solve climate and ESG challenges to support the net zero transition and cut emissions for SCOR and SCOR clients. Focus areas include ESG reporting, climate risk analysis and data, carbon offsetting as a solution, circular economy, diversity, equity, and inclusion (DEI) tech, and supply chain transparency. We also see several opportunities in the green insurance product space including solar production or maintenance guarantees, wind input parametric products, solar physical asset damage, cat-bond / ILS and insuring carbon credit projects. Thesis 3: We invest at the intersection of health and technology and partner with companies that help people live healthier lives, deliver in-force or claims outcome improvements, develop new business or add to SCOR’s Knowledge Center capabilities, and assist our clients to transform their offerings. We predominantly invest at late Seed / Series A and are interested in a broad range of B2B and B2B2C solutions across MedTech, wellness, wearables, data platforms, and software / AI platforms. How we operateIntegrated in the wider SCOR business: Direct access to the entirety of SCOR’s capabilities brings unique added value to our portfolio companies. SCOR’s core business has experts in nearly every country, line of business, and functional area, while SCOR Partners bring a broad range of client services, marketing and product development expertise. Mandate: focused on key markets in North America, EMEA and LATAM, with selective deployment in APAC and Africa. Stage and ownership: We invest Seed to Series B. We typically seek greater than 5% ownership at first investment, which may include a board seat (we have led or co-led half of our investments to date). Our investment is intended to make SCOR a meaningful contributor but leave founders room to manage their cap table. We look for a long-term investment and / or commercial relationship but do not seek a fast exit or to ultimately acquire portfolio companies. Partnership approach: we are active supporters of the companies we work with, assisting with technical input, recruitment, capital optimisation and more. The material growth of many insurtech MGAs and carriers has led to increasing demand for (re)insurance capacity; SCOR is a transparent, long-term partner. Insurtechs in SaaS and services segments, meanwhile, have benefited from SCOR’s long-standing client relationships, while SCOR benefits from bringing knowledge, links, and expertise regarding services with genuine value to our clients. We bring value to our portfolio companies by connecting them with other partner companies, as well as with founders and distribution leads in our network. Why partner with SCOR VenturesWe believe in fewer, deeper relationships over the long term. We are flexible and collaborative in our approach, tailoring a solution to your specific needs, in partnership with other insurers, reinsurers, and investors involved in your company as appropriate. We underwrite most major lines of business and geographies globally. We have a global network including insurance licenses but not a competing retail insurance arm. Insurers are our clients, so working with us does not limit your options to associate with insurers. In selected circumstances, we can offer access to Lloyd’s or SCOR’s insurance licenses in the U.S., Europe, Asia, Brazil, South Africa, and other markets. We look to move quickly with direct access to decision makers, whilst leveraging resources and expertise to ensure our partners can build relationships with the appropriate parts of our organization.

PsyMed Ventures is an early-stage venture fund investing in frontier mental health technologies. Our mission is to provide capital and support to companies that align healing, responsibility, and profitability. PsyMed’s focus areas include psychedelic medicine, neurotechnology, and precision psychiatry.

Intuitive Ventures invests in and accelerates the digital, therapeutic, diagnostic, and device ecosystems of minimally invasive care. Our unique access to Intuitive’s industry-leading knowledge, care delivery innovation, and commercial reach, empowers us to cultivate the potential of startups that are advancing positive outcomes in healthcare. Through our inaugural $100 million fund, Intuitive Ventures is focused on accelerating the future of minimally invasive care by moving the ecosystem forward. What we do Intuitive Ventures extends Intuitive's commitment to converging robotic systems, digital tools, and clinical need in search of new ways to understand, diagnose, treat, and manage disease. We apply Intuitive’s strengths and abilities in the fields of robotic surgery and minimally invasive care to support independent initiatives in four focus areas: Digital – transformative business models and solutions improving outcomes across the patient care continuum Therapeutics – precision focal therapeutics and biotech innovations delivered to the right patient at the right place and the right time Diagnostics – powering earlier disease detection and therapeutic activation across clinical pathways Devices – novel and digitally-native medical device platforms pushing the boundaries of patient care What sets us apart: Aligned for success – our nimble structure and financial alignment empower us to invest early and to support our portfolio companies pioneer markets Wealth of experience – we provide the resources and guidance needed to support our entrepreneurs and management teams reach their major milestones Deep strategic value – we leverage the unique strengths of Intuitive to accelerate the impact of our portfolio companies